UCD Conway SPHERE

UCD Conway SPHERE, launched in September 2015, is an interdisciplinary research group that works towards the understanding of a myriad of inflammatory diseases. Our group brings together clinical, academic and scientific collaborators nationally and internationally; harnessing unique tools to diagnose and understand a host of diseases, including thrombotic disorders. The acronym SPHERE describes the state-of the art translational interests of our group; “Systemic inflammatory disorders: role of blood Particles, Haemostatic factors and ExtRacEllular vesicles”.

Led by co-Directors Prof. Patricia Maguire and Prof. Fionnuala Ní Áinle, our group is based across several distinct research, academic and clinical centres in Dublin, Ireland under the umbrella of University College Dublin.

SPHERE_GroupFeb21
The UCD Conway SPHERE team: L-R Front row: Luisa Weiss, Prof. Fionnuala Ni Ainle, Prof. Patricia Maguire, Dr Paulina Szklanna. Back row: Dr Shane Comer, Dr Claire Murphy.

Our partner centres include;

  • UCD Conway Institute
  • UCD School of Biomolecular and Biomedical Science
  • UCD School of Medicine
  • Mater Misericordiae University Hospital
  • Rotunda Hospital

We are delighted to have a variety of funders and sponsors both from state bodies and from industry and we thank them for their continued support.

SPHERE_SponsorshipLogos

For further information about members of the group, our research and our publications, please follow the links below. 

Show/hide contentOpenClose All

Group Directors

Professor Patricia Maguire BSc, PhD

Scientific Director

SPHERE_Prof_Patricia_MaguirePatricia Maguire is Professor of Biochemistry in the School of Biomolecular & Biomedical Science and Principal Investigator and Fellow at the UCD Conway Institute. Together with Prof Fionnuala Ní Áinle, Patricia co-directs the UCD Conway SPHERE group which uses unique tools to diagnose and understand a host of inflammatory-based diseases, including Early-onset Preeclampsia, Multiple Sclerosis, and Venous ThromboEmbolism. The Conway SPHERE group have recently developed a new non-invasive blood-based diagnostics platform PALADIN (PlAteLet bAsed DIagNostics) that harnesses the power of platelets to uncover the secrets of disease. Through the ‘100 Platelet Releasate Project’ (100PREPS), the Conway SPHERE team have built a large internal database of disease-specific data, with the IP generating notable impact with multinational industry.

Patricia is also Director of the UCD Institute for Discovery, where the mission is to build & cultivate interdisciplinary connections across the UCD research community through initiatives around emerging areas/technologies, e.g., ‘AI for good’, ‘Plotting the Future’ and ‘Data for Healthcare’. She is also a member of the UCD Extended Leadership Group, central to the governance/decision making in UCD.

Email: patricia.maguire@ucd.ie

Twitter: @maguirepatr

 

Professor Fionnuala Ní Áinle MB, PhD, MRCPI, FRCPath

Clinical Director

SPHERE_Prof_Fionnuala_NiAinleProf Fionnuala Ní Ainle is a Consultant Haematologist at the Mater Misericordiae University Hospital (MMUH) and Rotunda Maternity Hospital, Dublin. She is also a Full Clinical Professor of Haematology in the School of Medicine, UCD. She is privileged to treat patients affected with thrombosis and has a strong interest in women’s issues in thrombosis and haemostasis. She acts as Chair of her Hospital and Regional venous thromboembolism (VTE) committees and is a founder member of VTE Ireland, a National Clinical VTE Working Group. She is co-organizer of the VTE Dublin thrombosis conference.

Co-Director of the UCD Conway SPHERE research group alongside Prof Maguire, Prof Ní Áinle’s research interests explore the role of blood coagulation and extracellular vesicles in the aetiology, management and therapy of clinical disorders, particularly disorders of pregnancy. She is also actively involved in international clinical trials.

Email: fniainle@mater.ie

Twitter: @fniainle

Lead Clinicians

Dr Barry Kevane MB, BCh, BAO, PhD, MRCPI, FRCPath

SPHERE_Dr_Barry_KevaneDr Barry Kevane completed undergraduate medical training in 2008 (MB, BCh, BAO; University College Cork) and following completion of initial postgraduate training in general internal medicine in 2011 (MRCPI; Royal College of Physicians of Ireland), he commenced higher specialist training in Haematology.  During the course of his Haematology training, Dr Kevane undertook a period of full-time clinical and translational research in the UCD Conway SPHERE Research Group, leading to the award of a PhD in translational medicine in 2017 (University College Dublin).  Having completed higher specialist training in Haematology in 2018, he was appointed to a consultant post at the National Coagulation Centre in St James’s Hospital, Dublin.  He was subsequently appointed to his current post of Consultant Haematologist with specialist interest in venous thromboembolism at the Mater Misericordiae University Hospital and Ireland East Hospital Group in September 2019. Dr Kevane is also a collaborative clinician on the EXCLAIM study.

Twitter: @BarryKevane

Email: barrykevane@mater.ie

Postdoctoral Research Fellows

Dr Paulina Szklanna BSc, PhD

SPHERE_Dr_Barry_KevanePaulina is a senior research fellow in the group. She graduated from UCD with a BSc (Hons) in Biochemistry and Molecular Biology in 2013  and with a PhD in Biochemistry in 2018. Paulina completed her PhD in the SPHERE research group. Her PhD research focused on biomarker identification through platelet releasate proteomics. In her current position, Paulina is focusing on utilising platelet and extracellular vesicle proteomics coupled with artificial intelligence to calculate risks for inflammatory disorders including cardiovascular disease, preeclampsia and multiple sclerosis.

Twitter: @szklannnp

Email: paulina.szklanna@ucdconnect.ie

 

 

Dr Shane Comer BSc, MSc, PhD

SPHERE_Dr_Shane_ComerShane joined the SPHERE research group as the Sanofi Newman Fellow in Haematology in October 2019. Shane graduated from UCD with a BSc (Hons) in physiology in 2014 and read immunology at TCD, graduating with an MSc in 2015. Shane completed his PhD in the olecular haemostasis research group in UCD School o f Medicine in 2019 under the supervision of Assoc Prof Albert Smolenski MD. His PhD research focused on the regulation of platelet activity by cyclic nucleotide signalling pathways. Shane also maintains a strong interest in science communication and outreach, participating in numerous initiatives both locally and nationally.  In the SPHERE group, Shane is working on the EXCLAIM study, investigating the impact of obesity on the anti-coagulant and anti-inflammatory effects of enoxaparin in HA-VTE patients.

Twitter: @Shane_Comer1

Email: shane.comer@ucdconnect.ie

Research Students

SPHERE_Luisa_WeissLuisa Weiss BSc, MSc

Luisa graduated from Fresenius University, Idstein, Germany, with a BSc (Hons) in Bioanalytical Science and Haematology in 2017, followed by an MSc in Biomolecular and Biomedical Science in UCD, graduating in 2018. Luisa joined the group in January 2018 to conduct research for her MSc thesis, developing a method for EV enrichment by size exclusion chromatography. In her PhD project, Luisa is investigating circulating extracellular vesicles in patients with cardiovascular disease.

Twitter: @lweiss1311

Email: luisa.weiss@ucdconnect.ie

 

 

Dr Claire Murphy MB, BCh, BAO, MRCPI (Paeds)

SPHERE_Dr_Claire_MurphyClaire started her MD (July 2019) with the SPHERE research group. She graduated from Trinity College Dublin with an Honours Degree in Medicine in 2013. She is a Specialist Registrar on the Irish Neonatal Higher Specialist Training Scheme. She was awarded a Clinical Research Fellowship through the National Children’s Research Centre to undertake her MD research project. This is a major research project being carried out in the Rotunda Hospital, Dublin in neonatal clotting and extracellular vesicles in preterm infants as part of her MD thesis.

Twitter: @claire_anne_neo

Email: murphc35@tcd.ie

 

Dr Daniel O’Reilly BSc, MB, BCh, BAO

Daniel graduated from Human Health and Disease in Trinity College Dublin in 2013, and Medicine in RCSI in 2017. He originally joined the group in 2018 as part of the academic track internship program and is currently working on platelet biology on neonates as part of his MSc. in Child Health and Paediatrics in Imperial College London alongside his clinical posts as a BST trainee in paediatrics.

Twitter: @Karate_RCHOP

Email: danieloreilly@alumnircsi.com

Visiting Students & Researchers

The UCD Conway SPHERE group regularly hosts visiting students and researchers from other labs, both nationally and internationally. Please contact us for further information.

Former Research Students:

  • Dr Paulina Szklanna (PhD – June 2018)
  • Dr Martin Parsons (PhD – Dec 2017)
  • Dr Barry Kevane (PhD – Dec 2017)
  • Ms Brid Holohan (MSc – April 2017)
  • Mr Tim Donlon (MSc – Dec 2016)
  • Dr Elaine Neary (PhD – Sept 2016; Prof Ní Áinle as co-supervisor with RCSI)
  • Dr Feidhlim Dervin (PhD – Dec 2015)
  • Dr Naheda Alkazemi (PhD – Oct 2014)
  • Dr Vishal Salunkhe (PhD – Jan 2013)
  • Dr Brian Steele (PhD- June 2010)
  • Dr Martina Foy (PhD- June 2005)
  • Dr Judith Coppinger (PhD- April 2004)
  • Dr Donal Harney (Masters in Research (MD)- December 2004).

 

Former Postdoctoral Staff:

  • Dr Karl Egan (2014-2019)
  • Dr Seamus Allen (2015-2017)
  • Dr Eugene Dempsey (2012-2014)
  • Dr Brian Steele (2011-2012)
  • Dr Iain Macaulay (2007-2009)
  • Dr Martina Foy (2005-2006)
  • Dr Judith Coppinger (2004-2005)

UCD Conway SPHERE is an interdisciplinary research group where people with a diverse range of skills are working on numerous projects with common themes throughout. Below is a list of the current, ongoing projects within our group.

The COCOON Study

The Cocoon Study is an international project which will examine blood coagulation in Covid-19 patients and its interplay with inflammation. Using advanced artificial intelligence and genomics technologies, the project will deliver enhanced thrombotic prevention strategies and a rapid diagnostic platform for personalised risk assessment. The study aims to address urgent clinical dilemmas and to develop novel solutions for existing diagnostic and therapeutic challenges.

  1. What is the optimal strategy to prevent thrombosis in Covid-19?
  2. Can we refine prediction of patients’ outcomes?
  3. Could anti-thrombotics represent a novel therapy?

SPHERE_Cocoon
The team aims to characterise the mechanisms driving hypercoagulability in Covid-19 and determine whether current standard thrombosis prevention measures sufficiently attenuate Covid-19 hypercoagulability. Achieving these aims will address the controversy surrounding optimal dosing of anti-thrombotics in Covid-19 and will also determine if other means of thrombosis prevention (such as anti-platelet therapy) may be of benefit.

Advanced proteomic analysis of plasma samples taken from across the spectrum of severity of infection will permit the identification of novel biomarkers which will be of superior specificity in comparison to existing markers (e.g. D-dimer). This will address the current limitations in this regard. In particular, analysis of platelet releasate (PR) in Covid-19 is predicted to yield valuable data – the UCD Conway SPHERE team have previously demonstrated that the proteomic signature of the PR is highly conserved among healthy individuals but can act as a ‘barcode for disease’ in multiple pathological states.

This novel and disruptive approach to risk stratification will arm clinicians with an affordable tool to channel resources appropriately and prevent unnecessary adverse outcomes through prevention of thrombotic complications. In collaboration with their international partners, the researchers believe that their approach will rapidly shape international clinical practice. More information can be found here.

AI PREMie

Preeclampsia (PET) is a condition of pregnancy that is difficult tto diagnose and kills 50,000 mothers and 500,000 babies globally every year. At present delivery of the pre-term baby is the only treatment and the safest option for the mother. But pre-term delivery can lead to long-term neurodevelopmental problems and even death. ConwaySPHERE is working to develop a new diagnostic test called AI PREMie to better predict PET severity and help save lives of both mothers and their babies.

SPHERE_AIPrem

AI PREMie is a risk stratification tool which identifies women with PET - and also how the condition will progress. Our AI PREMie tool assesses the pre-eclampsia risk based on circulating biomarkers in the plasma of pregnant mothers. This will give clinicians and other caregivers the opportunity to proactively plan pregnancies for at risk mothers, giving a clearer understanding if planning for delivery is necessary or if the baby can stay in utero allowing for further development as every day in utero counts.

The PALADINTM platform

The UCD Conway SPHERE team (Lead RPO) have developed a new blood-based innovative diagnostics platform PALADINTM (PlAteLet bAsed DIagNostics) that captures the power of the platelet releasate and uses advanced proteomics methods, state-of-the-art equipment and artificial intelligence to uncover useful molecular diagnostics for chronic disease. PALADINTM addresses the unmet need for an easily accessible, minimally invasive source for high-quality specific molecular biomarkers in numerous diseases. In contrary to most often used biofluids with very high dynamic range such as plasma or serum, PALADINTM harnesses the power of platelets which act as a natural ‘sieve’ and pick out important messages. Therefore, by analysing the platelet releasate the problem of highly abundant plasma proteins is resolved.

RIVEVE study

Rivaroxaban is a direct oral anticoagulant that has similar efficacy to warfarin in management of non-valvular atrial fibrillation (NVAF) and venous thromboembolism (VTE) and is currently prescribed in preference to warfarin. Rivaroxaban inhibits activated factor X (FXa), which converts prothrombin to thrombin. However, thrombin and FXa also mediate pro-inflammatory signalling, leading to further activation of coagulation. Recent studies revealed that Rivaroxaban downregulated pro-inflammatory protein expression and reduced complement activation, while warfarin failed to do so. Therefore, long-term inhibition of FXa may confer additional benefits that are unrelated to Rivaroxaban’s anticoagulant function but rather, are mediated by inhibition of pro-inflammatory signalling. Extracellular vesicles (EVs) are pro-inflammatory mediators that regulate many physiological and pathological processes. It is likely that the well-characterized anti-inflammatory effects of Rivaroxaban will be mirrored by similar effects upon plasma EVs. The RIVEVE study aims to characterize the influence of Rivaroxaban upon circulating pro-inflammatory EVs using a combination of single vesicle analysis and proteomics.

CAPE study (Coagulation Activation in PreEclampsia)

Preeclampsia (defined as new hypertension presenting after 20 weeks gestation with significant proteinuria) is a serious complication of pregnancy with potentially life-threatening consequences for both mother and baby. It is a major public health issue and a leading cause of death in the UK/Ireland. At present, preeclampsia diagnosis relies on error-prone techniques, furthermore the delivery of the preterm infant is the only curative treatment.  However, preterm delivery is associated with significant risk of foetal morbidity and mortality, especially in preterm births and even minor improvements in length of gestation at delivery confer significant survival benefits, therefore every day in utero counts. Using the PALADINTM platform, we have discovered candidate biomarkers that distinguish patients with preeclampsia from healthy pregnant women and that have the potential to calculate the risk of developing severe preeclampsia and whose preterm delivery can be delayed. Currently we are working on translating this research to an easier to use, plasma-based platform.

Multiple Sclerosis study

Multiple sclerosis is an inflammatory neurodegenerative disease of the central nervous system affecting over 2.3 million people worldwide. The progression of multiple sclerosis can differ among patients. Majority of patients suffer from relapsing remitting multiple sclerosis where they experience episodes of severe inflammation followed by a remittance from the disease. Whereas, some patients follow a progressive disease course from the outset and are classified as primary progressive multiple sclerosis. The complex aetiology of multiple sclerosis and the diverse symptoms make a definite diagnosis challenging. Multiple sclerosis is diagnosed by a combination of clinical attacks and lesions observed by MRI therefore the diagnosis can be prolonged in time and it is often hard to distinguish between disease types at the early stages of diagnostic process. Using the PALADINTM platform and ELISA, we have discovered candidate biomarkers capable of aiding the diagnosis of multiple sclerosis and distinguishing patients with relapsing remitting from primary progressive disease. Currently, we are assessing platelet-specific biomarkers and proteins we have discovered in multiple sclerosis patients and how these can be utilised as predictors for disease progression in patients.

Publications by UCD Conway SPHERE directors and group include:

  1. Kevane B, Allen S, Walsh K, Egan K, Maguire PB, Galligan MC, Kenny D, Savage R, Doran E, Lennon A, Neary E, Ní Áinle F. Dual endothelin-1 receptor antagonism attenuates platelet-mediated derangements of blood coagulation in Eisenmenger syndrome. Journal of Thrombosis and Haemostasis 2018 (in press)
  2. Parsons ME, O’Connell K, Allen S, Egan K, Szklanna P, McGuigan C, Ní Áinle F, Maguire PB. Thrombin generation correlates with disease duration in multiple sclerosis (MS): novel insights into the MS-associated prothrombotic state. Mult Scler J Exp Transl Clin. 2017 Dec 26;3(4):2055217317747624. doi: 10.1177/2055217317747624. 
  3. Monteith C, Egan K, O’Connor H, Maguire P, Kevane B, Szklanna PB, Cooley S, Malone F, Ní Áinle F. Early onset preeclampsia is associated with an elevated mean platelet volume (MPV) and a greater rise in MPV from time of booking compared with pregnant controls: results of the CAPE study. J Perinat Med. 2017 Dec 21. pii: /j/jpme.ahead-of-print/jpm-2017-0188/jpm-2017-0188.xml. doi: 10.1515/jpm-2017-0188. [Epub ahead of print]
  4. Parsons ME, McParland D, Szklanna PB, Guang MHZ, O’Connell K, O’Connor H, McGuigan C, Ní Áinle F, McCann A, Maguire P. A protocol for improved precision and increased confidence in Nanoparticle Tracking Analysis concentration measurements between 50-120 nm in biological fluids. Front Cardiovasc Med. 2017 Nov 3;4:68. doi: 10.3389/fcvm.2017.00068. eCollection 2017. PMID: 29164135
  5. Kelly B, Mendoza M, Carton E, Doughty H, Ní Áinle F. European Society of Intensive Care Medicine (ESICM) PACT (Patient-centred Acute Care Training) e-module (online learning course) on bleeding and thrombosis in the ICU. PACT, and ESICM product, is an up-to-date, on-line, modular curriculum for Intensive (Critical) Care Medicine. It is an educational resource aimed at advancing and harmonising the quality of Acute and Critical Care Medicine training. https://sso.esicm.org/auth/login?service=https%3A%2F%2Facademy.esicm.org%2Flogin%2Findex.php
  6. O’Shaughnessy F, Donnelly J, Cooley S, Deering M, Raman R, Gannon G, Hickey J, Holland A, Hayes N, Bennett K, Ní Áinle F, Cleary B (joint final authors). Thrombocalc: Implementation and uptake of personalized postpartum venous thromboembolism risk assessment in a high through-put obstetric environment. Acta Obstet Gynecol Scand. 2017 Nov;96(11):1382-1390. doi: 10.1111/aogs.13206. Epub 2017 Sep 21.PMID: 28832906 
  7. Kevane B, Egan K, Allen S, Maguire P, Neary E, Lennon A, Ní Áinle F. Endothelial barrier protective properties of LMWH: a novel potential tool in the prevention of cancer metastasis? Research and Practice in Thrombosis and Haemostasis 2017 (in press; doi 10.1002/rth2.12011)
  8. Egan K, O’Connor H, Kevane B, Malone F, Lennon A, Al Zadjali A, Cooley S, Monteith C, Maguire P, Szklanna P, Allen S, McCallion N, Ní Áinle F. Elevated plasma TFPI activity causes attenuated TF-dependent thrombin generation in early onset preeclampsia. Thromb Haemost. 2017 Jul 26;117(8):1549-1557. doi: 10.1160/TH16-12-0949. Epub 2017 Jun 1. PMID: 28569919 
  9. Kevane B, Ní Áinle F. Contraception and menstrual bleeding during venous thromboembolism treatment: Does current practice reflect expert option? (Editorial). Thromb Res. 2017 May;153:121-122. doi: 10.1016/j.thromres.2017.04.013. Epub 2017 Apr 12. No abstract available. PMID: 28413067
  10. Egan K, van Geffen JP, Ma Hui, Kevane B, Lennon A, Allen S, Neary E, Parsons M, Maguire P, Wynne K, O’Kennedy R, Heemskerk JWM, Ní Áinle F. Effect of platelet-derived β-thromboglobulins on coagulation. Thromb Res. 2017 Jun;154:7-15. doi: 10.1016/j.thromres.2017.03.023. Epub 2017 Mar 30. PMID: 28384443 
  11. Szklanna P, Nolan M, Wynne K, Egan K, Ni AInle F, Maguire P. Comparative proteomic analysis of trophoblast cell models reveals their differential phenotypes, potential uses and limitations. Proteomics. 2017 Mar 20. doi: 10.1002/pmic.201700037. [Epub ahead of print] PMID: 28317260
  12. Neary E, Ni Ainle F, El-Khuffash A, Cotter M, Kirkham C, McCallion N. Plasma transfusion to prevent
  13. intraventricular haemorrhage in very preterm infants. Protocol publication; Cochrane Database of Systematic Reviews 2016 (in press)
  14. McDonnell B, Glennon K, McTiernan A, Kirkham C, Kevane B, Donnelly J, Ní Áinle F. Adjustment of therapeutic LMWH to achieve specific target anti-FXa activity does not affect outcomes in pregnant patients with venous thromboembolism. J Thromb Thrombolysis. 2017 Jan;43(1):105-111. doi: 10.1007/s11239-016-1409-5.
  15. Egan K, Dillon A, Dunne E, Kevane B, Galvin Z, Maguire P, Kenny D, Stewart S, Ní Áinle F. Increased soluble GPVI levels in cirrhosis: evidence for early in vivo platelet activation. J Thromb Thrombolysis. 2017 Jan;43(1):54-59. doi: 10.1007/s11239-016-1401-0.
  16. Barrett A, Kevane B, Hall P, Ní Áinle F, Breslin T. Screening for malignancy in patients with unprovoked venous thromboembolism: a single-centre retrospective case-series. Clin Appl Thromb Hemost. 2016 Jan 1:1076029616659694. doi: 10.1177/1076029616659694. [Epub ahead of print] PMID: 27443696
  17. Bleker, SM, Buchmüller A, Chauleur C, Ní Áinle F, Donnelly J, Verhamme V, Jacobsen AF, Ganzevoort W, Prins M, Beyer-Westendorf J, DeSancho M, Konstantinides S, Pabinger I, Rodger M, Decousus H, Middeldorp S, for the Highlow investigators. Low-molecular-weight heparin to prevent recurrent VTE in pregnancy: rationale and design of the Highlow study, a randomized trial of two doses. Thrombosis Research 2016 Aug;144:62-8. doi: 10.1016/j.thromres.2016.06.001.PMID: 27289488
  18. Crowley M, Kevane B, O’Shea S, Quinn S, Egan K, Gilligan O, Ní Ainle F. Plasma thrombin generation and sensitivity to activated protein C among patients with myeloma and monoclonal gammopathy of undetermined significance. Clin Appl Thromb Hemost. 2016 Sep;22(6):554-62. doi: 10.1177/1076029615625825. PMID: 26759370
  19. Husarova V, Donnelly G, Doolan A, Garstka M, Ní Áinle F, McCaul C. Preferences of Jehovah’s Witnesses regarding haematological supports in an obstetric setting: experience of a single university teaching hospital. Int J Obstet Anesth. 2015 Sep 25. pii: S0959-289X(15)00133-8. doi: 10.1016/j.ijoa.2015.09.005. [Epub ahead of print] PMID: 26597403
  20. Neary E, McCallion N, Kevane B, Cotter M, Egan K, Regan I, Kirkham C, Mooney C, Coulter-Smith S, Ní Áinle F. Coagulation indices in very preterm infants from cord blood and postnatal samples. Journal of Thrombosis and Haemostasis 2015 Nov;13(11):2021-2030. doi: 10.1111/jth.13130. Epub 2015 Sep 25. PMID:26334448
  21. Egan K, Kevane B, Ní Áinle F. Elevated venous thromboembolism risk in preeclampsia: molecular mechanisms and clinical impact. Biochem Soc Trans. 2015 Aug 1;43(4):696-701. Epub 2015 Aug 3. Review. PMID: 26551715
  22. Werth S, Breslin T, NiAinle F, Beyer-Westendorf J. Bleeding Risk, Management and Outcome in Patients Receiving Non-VKA Oral Anticoagulants (NOACs). Am J Cardiovasc Drugs. Am J Cardiovasc Drugs. 2015 Aug;15(4):235-42. doi: 10.1007/s40256-015-0123-6. PMID: 25940651
  23. Neary E, Ni Ainle F, Cotter M, McCallion N. Coagulation values in extreme premature infants. Transfusion. 2014 Aug;54(8):2134. doi: 10.1111/trf.12734 2014 Aug;54(8):2134. doi: 10.1111/trf.12734. PMID: 25130336
  24. Langabeer SE, Haslam K, Linders J, Percy MJ, Conneally E, Hayat A, Hennessy B, Leahy M, Murphy K, Murray M, Ni Ainle F, Thornton P, Sargent J. Molecular heterogeneity of familial myeloproliferative neoplasms revealed by analysis of the commonly acquired JAK2, CALR and MPL mutations. Fam Cancer. 2014 Dec;13(4):659-63. doi: 10.1007/s10689-014-9743-2. PMID: 25103330
  25. Donnellan E, Kevane B, Bird BR, Ainle FN. Cancer and venous thromboembolic disease: from molecular mechanisms to clinical management. Curr Oncol. 2014 Jun;21(3):134-43. doi: 10.3747/co.21.1864. PMID: 24940094 
  26. Kevane B, McKenna P, Walsh K, Donnelly JC, Flood K, Cullen M, Bowen M, Thornton P, Loughrey J, Coulter-Smith S, Ainle FN. Haemorrhagic and thrombotic complications in pregnant women with acquired and congenital cardiac disease. J Perinat Med. 2015 Mar;43(2):165-9. doi: 10.1515/jpm-2014-0088. PMID: 25014516
  27. Scully M, Thomas M, Underwood M, Watson H, Langley K, Camilleri RS, Clark A, Creagh D, Rayment R, Mcdonald V, Roy A, Evans G, McGuckin S, Ni Ainle F, Maclean R, Lester W, Nash M, Scott R, O Brien P; collaborators of the UK TTP Registry. Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes. Blood. 2014 Jul 10;124(2):211-9. doi: 10.1182/blood-2014-02-553131. Epub 2014 May 23. PMID: 24859360
  28. Macaulay IC, Thon JN, et al, He X, Fitzgerald DJ, Italiano Jr. JE, Maguire PB. (2013) Canonical Wnt signaling in Megakaryocytes regulates Proplatelet formation. Blood. 121,88-96.
  29. Steele BM, Harper MT, Smolenski AP, Alkazemi A, Poole AW, Fitzgerald DJ, Maguire PB (2012) WNT-3a modulates platelet function by regulating small GTPase activity. FEBS Lett. 586:2267-2272.
  30. Maguire PB, Steele BM, Fitzgerald DJ (2011) Novel Platelet Signalling Pathways Identified via Proteomics. Current Proteomics. 8: 208-215.
  31. Johnston O, Cassidy H, O'Connell S, O'Riordan A, Gallagher W, Maguire PB, Wynne K, Cagney G, Ryan MP, Conlon PJ, McMorrow T (2011). Identification of β2-microglobulin as a urinary biomarker for chronic allograft nephropathy using proteomic methods. Proteomics Clin Appl. 5:422-431.
  32. Ní Áinle F, O’Donnell JS, Johnson JA, Brown L, Gleeson EM, Smith OP, Preston RJ. Activated protein C N-linked glycans modulate cytoprotective signaling function on endothelial cells. J Biol Chem. 2011 Jan 14;286(2):1323-30. doi: 10.1074/jbc.M110.159475. Epub 2010 Nov 2. PMID: 21044954 
  33. Goodall AH, Burns P , Salles I, Macaulay IC, Jones C, Ardissino D, de Bono B, Bray SL, Deckmyn H, Dudbridge F, Fitzgerald DJ, Garner SF, Gusnanto A, Koch K, Langford C, O’Connor M, Rice CM, van der Schoot E, Stemple D, Stephens J, Trip MD, Samani NJ, Watkins NA, Maguire PB, Ouwehand WH, on behalf of the Bloodomics Consortium (2010) Transcription Profiling in Human Platelets Reveals LRRFIP1 as a Novel Protein Regulating Platelet Function. Blood. 116:4646-4656. 
  34. Steele BM, Harper MT, Macaulay IC, Morrell CN, Perez-Tamayo A, Foy M, Habas R, Poole AW, Fitzgerald DJ, Maguire PB. (2009) Canonical WNT signalling negatively regulates platelet function. Proc. Natl. Acad. Sci. USA. 106, 19836-19841.
  35. Bernimoulin M, Waters EK, Foy M, Steele BM, Sullivan M, Falet H, Walsh MT, Barteneva N, Geng JG, Hartwig JH, Maguire PB, Wagner DD. (2009) Differential stimulation of monocytic cells results in distinct populations of microparticles. J. Thromb. Haem. 7, 1019-1028. 
  36. Ní Áinle F, Preston RJ, Jenkins PV, Nel HJ, Johnson JA, Smith OP, White B, Fallon PG, O'Donnell JS. Protamine sulfate down-regulates thrombin generation by inhibiting factor V activation. Blood 2009 Aug 20;114(8):1658-65. doi: 10.1182/blood-2009-05-222109. Epub 2009 Jun 16. PMID: 19531655 
  37. Preston RJ, Tran S, Johnson JA, Ní Áinle F, Harmon S, White B, Smith OP, Jenkins PV, Dahlbäck B, O'Donnell JS. Platelet factor 4 impairs the anticoagulant activity of activated protein C. J Biol Chem. 2009 Feb 27;284(9):5869-75. doi: 10.1074/jbc.M804703200. Epub 2009 Jan 6. PMID: 19129181 
  38. Harmon S, Preston RJ, Ní Áinle F, Johnson JA, Cunningham MS, Smith OP, White B, O'Donnell JS. Dissociation of activated protein C functions by elimination of protein S cofactor enhancement. J Biol Chem. 2008 Nov 7;283(45):30531-9. doi: 10.1074/jbc.M802338200. Epub 2008 Sep 8. PMID: 18779332 
  39. Ní Áinle F, Wong A, Appleby N, Byrne B, Regan C, Hassan T, Milner M, Sullivan AO, White B, O'Donnell J. Efficacy and safety of once daily low molecular weight heparin (tinzaparin sodium) in high risk pregnancy. Blood Coagul Fibrinolysis. 2008 Oct;19(7):689-92. doi: 10.1097/MBC.0b013e32830b14ef.a. PMID: 18832911
  40. Behan AT, Foy M, Wynne K, Clarke M, Sullivan M, Cotter DR, Maguire PB. (2008) Analysis of membrane microdomains-associated proteins in the insular cortex of human brain. Proteomics Clinical Applications, 1, 1324-1331.
  41. Feighery R, Maguire P, Ryan MR, McMorrow T. (2008) A proteomic approach to immune-mediated epithelial-mesenchymal transition. Proteomics Clinical Applications, 2, 1110-1117.
  42. O'Riordan A, Johnston O, McMorrow T, Wynne K, Maguire P, Hegarty J, McCormick A, Watson AJ, Cagney G, Gallagher WM, Ryan MR. (2008) Identification of Apolipoprotein AI as a serum biomarker of chronic kidney disease in liver transplant recipients, using proteomic techniques. Proteomics Clinical Applications, 2, 1338-1348. 
  43. Kerrigan SW, Jakubovics NS, Keane C, Maguire P, Wynne K, Jenkinson HF, Cox D. (2007) Role of Streptococcus gordonii surface proteins SspA/SspB and Hsa in platelet function. Infect Immun. 75, 5740-5747.
  44. Coppinger JA, O'Connor RI, Wynne K, Flanagan M, Sullivan M, Maguire PB, Fitzgerald DJ, Cagney G. (2007) Moderation of the platelet releasate response by aspirin. Blood. 109, 4786-92.
  45. Foy M. & Maguire PB. (2007) Recent advances in the characterisation of the platelet membrane system in platelets. Curr. Pharm. Des. 13, 2647-2655.
  46. Coppinger JC & Maguire PB. (2007). Insights into the platelet releasate. Curr Pharm Des. 13, 2640-2646.
  47. Maguire PB, Belton O, O’Donoghue N & Coppinger JC. (2007) “Platelet-endothelial interactions” in, The Endothelium: A Comprehensive Reference. Edited by William C. Aird. Cambridge Univerity Press, Cambridge, UK.
  48. Foy M., Harney D.F, Wynne K.J & Maguire PB (2007) Enrichment of phospho-tyrosine proteome of human platelets by immunoprecipitation. Methods Mol. Biol. 357, 313-318.
  49. Coppinger JC, Fitzgerald DJ & Maguire PB (2007) Analysis of the platelet releasate. Methods Mol. Biol. 357, 307-312.
  50. Kelly P, Maguire PB, Bennett M, Fitzgerald DJ, Edwards R, Thiede B, Treumann A, Collins J, O'Sullivan GC, Shanahan F, Dunne C. (2005) Correlation of probiotic Lactobacillus salivarius growth phase with its cell wall-associated proteome. FEMS Microbiol. Lett. 252, 153-159.
  51. Maguire PB, Foy M & Fitzgerald DJ (2005) Using proteomics to identify potential therapeutic targets in platelets. Biochem. Soc. Trans. 33, 409-412.
  52. Coppinger JA, Cagney G, Toomey S, Kislinger T, Belton O, McRedmond J, Cahill D, Emili A, Fitzgerald DJ & Maguire PB. (2004) Proteomic characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood. 103, 2096-2104.
  53. Maguire PB. (2004) Platelet proteomics: identification of potential therapeutic targets. Pathophysiol. Haemost. Thromb. 33(5-6):481-6. 
  54. Maguire PB, Moran N, Cagney G & Fitzgerald DJ. (2004) Application of proteomics to the study of platelet regulatory mechanisms. Trends Cardiovasc. Med. 14(6):207-20. 
  55. McRedmond J, Park S, Reilly D, Coppinger JA, Maguire PB, Shields D, Fitzgerald DJ. (2004) Integration of transcriptomics and genomics in platelets: a profile of platelet proteins and platelet-specific genes. Mol. Cell. Proteomics. 3, 133-144. 
  56. Maguire PB & Fitzgerald DJ. (2003) Platelet proteomics. J. Thromb. Haemost. 1, 1593-1601. 
  57. Maguire PB, Wynne KJ, & Fitzgerald DJ. (2002). The phosphotyrosine proteome isolated from human platelets. Bioforum International, 6, 326-327. 
  58. Maguire PB, Wynne KJ, Harney DF, O’Donoghue NM, Stephens G, Fitzgerald DJ (2002) Identification of the phosphotyrosine proteome from thrombin activated platelets. Proteomics, 2, 642-648.
  59. Ohlendieck K, Froemming GR, Murray BE, Maguire PB, Leisner E, Traub I & Pette D. (1999). Effects of chronic low-frequency stimulation on Ca2+-regulatory membrane proteins in rabbit fast muscle. Pflugers Arch, Eur. J. Physiol. 438, 700-708.
  60. Culligan K, Mackey A, Finn D, Maguire PB & Ohlendieck K. (1998) Role of dystrophin isoforms and associated proteins in muscular dystrophy (review). Int. J. Mol. Med. 2, 639-648.
  61. Murray B. E., Froemming G. R., Maguire P. B. & Ohlendieck K. (1998) Excitation-contraction-relaxation cycle: role of Ca2+-regulatory membrane proteins in normal, stimulated and pathological skeletal muscle (review). Int. J. Mol. Med. 1, 677-687.
  62. Maguire P. B., Briggs F. N., Lennon N. & Ohlendieck K. (1997) Oligomerization is an intrinsic property of calsequestrin in normal and transformed skeletal muscle. Biochem. Biophys. Res. Comm. 240, 721-727.
  63. Maguire P.B. & Ohlendieck K. (1996) Oligomerization of sarcoplasmic reticulum Ca2+-ATPase from rabbit skeletal muscle. FEBS Lett. 396, 115 -118.